Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy

Hideki Kanai, Hideki Marushima, Naofumi Kimura, Takamasa Iwaki, Masaya Saito, Haruka Maehashi, Keiko Shimizu, Makiko Muto, Takahiro Masaki, Kiyoshi Ohkawa, Keitaro Yokoyama, Masaaki Nakayama, Tohru Harada, Hiroshi Hano, Yoshiaki Hataba, Takahiro Fukuda, Masahiko Nakamura, Naoto Totsuka, Shutaro Ishikawa, Yasuki UnemuraYuji Ishii, Katsuhiko Yanaga, Tomokazu Matsuura

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

An extracorporeal bioartificial liver (BAL) that could prevent death from hepatic encephalopathy in acute hepatic insufficiency was aimed to develop. A functional human hepatocellular carcinoma cell line (FLC-4) was cultured in a radial-flow bioreactor. The function of the BAL was tested in mini-pigs with acute hepatic failure induced by α-amanitin and lipopolysaccharide. When the BAL system was connected with cultured FLC-4 to three pigs with hepatic dysfunction, all demonstrated electroencephalographic improvement and survived. Relatively low plasma concentrations of S-100 β protein, as a marker of astrocytic damage, from pigs with hepatic failure during BAL therapy were noted. BAL therapy can prevent irreversible brain damage from hepatic encephalopathy in experimental acute hepatic failure.

Original languageEnglish
Pages (from-to)148-151
Number of pages4
JournalArtificial Organs
Volume31
Issue number2
DOIs
Publication statusPublished - 2007 Feb

Keywords

  • Acute hepatic failure
  • Astrocytes
  • Cerebral edema
  • Radial-flow bioreactor
  • α-Amanitin

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

Fingerprint

Dive into the research topics of 'Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy'. Together they form a unique fingerprint.

Cite this